Benzinga · Aug 14, 2026
HC Wainwright & Co. Reiterates Buy on Celcuity, Maintains $155 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $155 price target.
CE
NASDAQ · CELC
Celcuity Inc.
Healthcare · Biotechnology
$93.24
Up+$0.80 (+0.87%)
Updated Aug 19, 2026, 8:23 AM
SID Score
5.1/10
Composite research score
Smart Money
54/100
Neutral
- Market cap
- 4.66B
- P/E ratio
- -27.72
- Dividend yield
- 0.00%
- 52-week range
- $44.42 – $151.02
- Volume
- 532.97K
- Avg. volume
- 1.12M
Price performance
CELC price history
1M range · 21 trading sessions · Daily adjusted prices
CELC closed at $93.24 after 21 trading sessions, up 1.69% for the selected period.
- Last close
- $93.24
- Period change
- +1.69%
- Period low
- $82.27
- Period high
- $93.25
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $92.38 | $94.12 | $91.29 | $93.24 | 532.97K |
| Aug 17, 2026 | $92.99 | $93.00 | $90.59 | $92.44 | 900.98K |
| Aug 14, 2026 | $83.04 | $95.56 | $83.04 | $92.00 | 1.33M |
| Aug 13, 2026 | $92.08 | $92.99 | $86.405 | $86.60 | 1.42M |
| Aug 12, 2026 | $88.72 | $92.56 | $88.05 | $92.08 | 795.24K |
| Aug 11, 2026 | $92.15 | $92.20 | $87.63 | $88.11 | 619.4K |
| Aug 10, 2026 | $92.35 | $93.67 | $90.135 | $90.79 | 787.05K |
| Aug 7, 2026 | $94.99 | $95.155 | $90.39 | $92.78 | 543.22K |
| Aug 6, 2026 | $92.92 | $95.205 | $91.81 | $93.25 | 569.61K |
| Aug 5, 2026 | $93.68 | $94.41 | $90.82 | $92.92 | 772.01K |
| Aug 4, 2026 | $88.34 | $93.39 | $88.34 | $92.49 | 713.93K |
| Aug 3, 2026 | $85.16 | $87.99 | $83.4284 | $87.72 | 557.33K |
| Jul 31, 2026 | $88.50 | $88.50 | $85.46 | $86.38 | 677.93K |
| Jul 30, 2026 | $85.03 | $87.97 | $83.33 | $87.64 | 1.32M |
| Jul 29, 2026 | $82.77 | $84.72 | $80.30 | $83.26 | 1.37M |
| Jul 28, 2026 | $82.09 | $82.98 | $78.60 | $82.46 | 1.96M |
| Jul 27, 2026 | $83.30 | $85.05 | $81.01 | $82.27 | 1.76M |
| Jul 24, 2026 | $89.56 | $89.56 | $82.23 | $82.62 | 1.29M |
| Jul 23, 2026 | $89.07 | $91.665 | $87.96 | $88.34 | 1.75M |
| Jul 22, 2026 | $90.20 | $92.66 | $89.24 | $90.14 | 792.95K |
| Jul 21, 2026 | $87.99 | $92.2425 | $87.2101 | $91.69 | 1.86M |
Latest CELC news
The latest Smart Investors Daily articles mentioning CELC.
Stock researchCompany · Overview
CELC research
Overview
Company profile and research snapshot.
Company profile
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $86.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Citizens | Market Outperform | — |
| Aug 17, 2026 | Guggenheim | Buy | — |
| Aug 14, 2026 | Needham | Buy | — |
| Aug 14, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 14, 2026 | Stifel | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 14, 2026
Celcuity: REVTORPYK Is Now A Commercial Story
Celcuity Inc. stock outlook: FDA approval and NCCN inclusion de-risk REVTORPYK launch, strong cash runway to 2029. Click for this CELC update.
Benzinga · Aug 14, 2026
Celcuity Analysts Slash Their Forecasts After Q2 Loss
Celcuity Inc (NASDAQ:CELC) reported better-than-expected Q2 losses of $1.07 per share. Analysts are optimistic with price target cuts by Needham and Stifel.
Benzinga · Aug 14, 2026
Stifel Maintains Buy on Celcuity, Lowers Price Target to $150
Stifel analyst Stephen Willey maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $175 to $150.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
